Saturday, 24 February 2018 - 6:55
  • it
  • de
  • en
  • fr

Pathology

Japan-based Shionogi develops powerful drug to treat influenza

Japan-based pharmaceutical group Shionogi has reported that it has developed a therapy eliminating the A and B influenza virus in 24 hours with a single dose–a far better result than Roche’s Tamiflu, which requires two doses and a minimum of…

Gilead’s Biktarvy (HIV) approved

FDA has granted Gilead approval for its novel drug Biktarvy, for the treatment of HIV. Biktarvy combines the novel inhibitor bictegravir with Gilead’s molecules emtricitabine and tenofovir alafenamide. It is a once-daily treatment–a regimen tested in as many as 4…

Spread of diabetes in the world: state of the art

Consultancy IQVIA (formerly IMS Health Quintiles) has published a brief study analyzing the spread of diabetes mellitus (type-2) in the world and the predictions for the years to come. The study shows that diabetes has now reached pandemic proportions, with…

New developments for Roche’s novel autism therapy

FDA has granted Breakthrough Therapy designation to Roche’s RG7314 investigational therapy (balovaptan), developed by the Switzerland-based group for the treatment of autism. Balovaptan is a V1A receptor antagonist, which has already shown efficacy against autism in various clinical trials. Roche’s…

Big Pharma invests in research for new antibiotics ($2bn)

Big pharma keeps investing in research for new antibiotics to fight drug-resistant infections. A recent survey by the International Federation of Pharmaceutical Manufacturers has revealed that 22 international drugmakers–including AstraZeneca, GSK and MSD–invested a total of over $2bn in research…

Simple test to detect cancer even at early stages

The prestigious journal Science has published a long article by a team of scientists from Johns Hopkins Kimmel Cancer Center in Baltimore, led by Nickolas Papadopoulos. The article is about a simple blood test that can detect eight types of…

Positive Phase III results for Ipsen’s liver cancer therapy, shares soar

Ipsen and its partner Exelixis have announced they have interrupted the Phase III Celestial clinical trial, since the investigational therapy Cabometyx (cabozantinib) has reached its endpoints earlier than expected. Specifically, Cabometyx has been reported to provide a statistically significant improvement…

Hopes for Alzheimer’s therapy focus on Biogen (aducanumab)

Academia and investors were dejected as Pfizer last week announced it would end research for Alzheimer’s treatments. The few multinationals still working on Alzheimer’s – Eli Lilly, Biogen and Novartis – have recently said they are determined to keep funding…

CRISPR technology for the treatment of deafness with genetic causes

The journal Nature has published an article reporting a new, significant success of CRISPR technology–Cas9. A team of researchers led by David R. Liu, at Rice University of Houston has succeeded in correcting, using CRISPR technology, a mutant form of…

Oncology business to keep leading pharma market in 2018

Oncology will maintain its leading position in the pharma industry in 2018. The cancer drug market will be worth approximately $100bn in 2017. The 30 main cancer drugs have generated approximately 12% of their respective manufacturers’ revenues over the first…

Life expectancy in US keeps decreasing

Life expectancy in the US is steadily decreasing and it went from 78.7 years old in 2015 to 78.6 in 2016, contrarily to the trend observed in other industrialized countries. The figures were announced by the Centers for Disease Control…

The worrisome increase of HIV spread in Russia

The spread of HIV in Russia seems unstoppable, although the Government last year implemented significant measures to control the spread of the disease. Experts expect 100,000 new infections by the end of the year, in contrast with the downward trend…

Amgen announces Phase III results from migraine therapy

Amgen yesterday reported that The New England Journal of Medicine had published results from the Phase III STRIVE clinical trial, assessing the investigational drug Aimovig (erenumab) vs placebo for the prevention of chronic migraine. Aimovig is a monoclonal antibody that…

Excellent Phase III results for Teva’s chronic migraine therapy

The New England Journal of Medicine yesterday reported in a relevant article the results from the Phase III HALO trial, designed to assess the investigational drug fremanezumab, developed by Teva, on 1130 patients. The medicine, believed to be the most…

Gloomy results from the research for an Alzheimer’s therapy

Alzheimer’s is a pathology affecting 44 million people globally, with an extremely high social cost, which – for example – is close to $249bn pa in the US. Only four approved therapies are currently available to ease the effects of…

Antimicrobial resistance: new research opens way to block transmission

Some researchers at the Université de Montréal have investigated the antimicrobial resistance mechanisms to antibiotics and the new possible ways to prevent it. As already known, this issue is a worldwide healthcare emergency. Scientists have focused on transfer of plasmids,…

Can a genetic mutation protect from diabetes?

Results from a study establishing a link between a genetic mutation, a reduction in diabetes cases and lower glycaemia levels in fasting patients have been published on Science Advances. Some researchers at Northwestern University Feinberg School of Medicine, Chicago, have…

New antibiotic therapies: what future?

The state of the art of new substances against bacterial infections has been checked at the IDWeek 2017, organized by the Infectious Disease Society of America (IDSA). One of the drugs recently approved by the FDA is the fixed-dose combination…